• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

certolizumab - Articles and news items

Golimumab shows higher treatment persistence rates in patients with IMRD

Industry news / 16 February 2016 / Victoria White

A study shows that patients initiating treatment with golimumab had significantly higher persistence rates than those initiating treatment with adalimumab or etanercept at 3 years.

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringFIND OUT MORE
+ +